BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 9815766)

  • 1. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.
    Jackman AL; Kimbell R; Aherne GW; Brunton L; Jansen G; Stephens TC; Smith MN; Wardleworth JM; Boyle FT
    Clin Cancer Res; 1997 Jun; 3(6):911-21. PubMed ID: 9815766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
    Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
    Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo.
    Jackman AL; Taylor GA; O'Connor BM; Bishop JA; Moran RG; Calvert AH
    Cancer Res; 1990 Sep; 50(17):5212-8. PubMed ID: 2386929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
    Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
    Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and biological studies on 2-desamino-2-methylaminopterin, an antifolate the polyglutamates of which are more potent than the monoglutamate against three key enzymes of folate metabolism.
    Rosowsky A; Galivan J; Beardsley GP; Bader H; O'Connor BM; Russello O; Moroson BA; DeYarman MT; Kerwar SS; Freisheim JH
    Cancer Res; 1992 Apr; 52(8):2148-55. PubMed ID: 1313737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carrier- and receptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity.
    Westerhof GR; Schornagel JH; Kathmann I; Jackman AL; Rosowsky A; Forsch RA; Hynes JB; Boyle FT; Peters GJ; Pinedo HM
    Mol Pharmacol; 1995 Sep; 48(3):459-71. PubMed ID: 7565626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
    McGuire JJ; Magee KJ; Russell CA; Canestrari JM
    Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.
    Jackman AL; Alison DL; Calvert AH; Harrap KR
    Cancer Res; 1986 Jun; 46(6):2810-5. PubMed ID: 2938731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity.
    Jackman AL; Kimbell R; Brown M; Brunton L; Boyle FT
    Anticancer Drug Des; 1995 Oct; 10(7):555-72. PubMed ID: 7495479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
    Rhee MS; Galivan J; Wright JE; Rosowsky A
    Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase.
    Duch DS; Banks S; Dev IK; Dickerson SH; Ferone R; Heath LS; Humphreys J; Knick V; Pendergast W; Singer S
    Cancer Res; 1993 Feb; 53(4):810-8. PubMed ID: 8428362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
    Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
    Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
    Jackman AL; Kelland LR; Kimbell R; Brown M; Gibson W; Aherne GW; Hardcastle A; Boyle FT
    Br J Cancer; 1995 May; 71(5):914-24. PubMed ID: 7537518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
    Li WW; Tong WP; Bertino JR
    Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
    Takemura Y; Ohnuma T
    Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
    Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
    Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
    van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
    Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.
    Webley SD; Hardcastle A; Ladner RD; Jackman AL; Aherne GW
    Br J Cancer; 2000 Sep; 83(6):792-9. PubMed ID: 10952785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of human acute leukemia cell line resistant to ZD9331, a non-polyglutamatable thymidylate synthase inhibitor.
    Kobayashi H; Takemura Y; Miyachi H
    Cancer Chemother Pharmacol; 1998; 42(2):105-10. PubMed ID: 9654109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.